PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.23%
EBIT growth below 50% of CRVO's 294.93%. Michael Burry would suspect deeper competitive or cost structure issues.
22.23%
Operating income growth under 50% of CRVO's 504.98%. Michael Burry would be concerned about deeper cost or sales issues.
18.34%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
32.95%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
32.95%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
21.91%
Slight or no buybacks while CRVO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
21.91%
Slight or no buyback while CRVO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
46.02%
OCF growth 1.25-1.5x CRVO's 41.30%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
46.06%
FCF growth similar to CRVO's 46.24%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8783.56%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
85.25%
OCF/share CAGR of 85.25% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
76.39%
3Y OCF/share CAGR of 76.39% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-13944.86%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
85.03%
Net income/share CAGR of 85.03% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
64.22%
3Y net income/share CAGR of 64.22% while CRVO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
5293.49%
Equity/share CAGR of 5293.49% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
188.65%
Equity/share CAGR of 188.65% while CRVO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
367.41%
Equity/share CAGR of 367.41% while CRVO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-38.36%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-22.47%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.